Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Considerations and challenges of integrating CAR-T and transplantation in B-ALL

Peihua Lu, MD, Lu Daopei Hospital, Langfang, China and Lu Daopei Institute of Hematology, Beijing, China, talks on considerations and challenges of the integration of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy and transplantation in patients with B-cell acute lymphoblastic leukemia (B-ALL). In particular, Dr Lu highlights challenges around a high initial complete response (CR) rate with a low duration of response with CAR-T therapy and discusses the benefit of bridging to consolidation allogeneic stem cell transplantation. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.